Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura

New England Journal of Medicine

Volumn 380, Issue 4, 2019, Pages 335-346

  Scully, M ^a   Cataland, S R ^b   Peyvandi, F ^c,d   Coppo, P ^e   Knol P ^f   Kremer Hovinga, J A ^g   Metjian, A ^h   De La Rubia, J ⁱ   Pavenski, K ^j   Callewaert, F ^k   Biswas, D ^k   De Winter, H ^k   Zeldin, R K ^k  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b OHIO STATE UNIVERSITY   (United States)

^c MAGGIORE HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e HÔPITAL SAINT ANTOINE   (France)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF BERN   (Switzerland)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^j UNIVERSITY OF TORONTO   (Canada)

^k UCB   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPLACIZUMAB; PLACEBO; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAMTS13 PROTEIN, HUMAN; FIBRINOLYTIC AGENT; NANOBODY; VON WILLEBRAND FACTOR;

ADULT; ADVERSE EVENT; AGED; ARTICLE; BRAIN ISCHEMIA; CAUSE OF DEATH; CLINICAL OUTCOME; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME ACTIVITY; EPISTAXIS; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMA EXCHANGE; PLATELET COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK REDUCTION; SKIN BLEEDING; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLEEDING; BODY MASS; CHEMICALLY INDUCED; CLINICAL TRIAL; GINGIVA DISEASE; INTENTION TO TREAT ANALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; YOUNG ADULT;

ADAMTS13 PROTEIN; ADOLESCENT; ADULT; AGED; BODY MASS INDEX; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; GINGIVAL DISEASES; HEMORRHAGE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SINGLE-DOMAIN ANTIBODIES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 85060365954     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1806311     Document Type: Article

References (25)

1. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11-8.
2. Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: The French TMA Reference Center experience. PLoS One 2010; 5(4): e10208.
3. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393-7.
4. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-35.
5. Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-Term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 2013; 122: 2023-9.
6. Kremer Hovinga JA, Vesely SK, Terrell DR, Lmle B, George JN Survival and relapse in patients with thrombotic thrombocytopenic purpura, Blood 2010, 115:1500-11
7. Thejeel B, Garg AX, Clark WF, Liu AR, Iansavichus AV, Hildebrand AM. Longterm outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review. Am J Hematol 2016; 91: 623-30.
8. Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood 2016; 128: 2175-8.
9. Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008; 141: 651-8.
10. Bettoni G, Palla R, Valsecchi C, et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 1556-65.
11. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-9.
12. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012; 120: 3603-10.
13. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016; 374: 511-22.
14. Peyvandi F, Callewaert F. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016; 374: 2497-8.
15. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2017; 15: 1448-52.
16. Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017; 15: 312-22.
17. Benhamou Y, Boelle PY, Baudin B, et al. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura: experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost 2015; 13: 293-302.
18. Lmle B., Kremer Hovinga JA, George JN. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica 2008 93:172-7
19. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 2013; 11: 481-90.
20. Knovich MA, Farland A, Owen J. Long-Term management of acquired thrombotic thrombocytopenic purpura using serial plasma ADAMTS13 measurements. Eur J Haematol 2012; 88: 518-25.
21. Cataland SR, Yang SB, Witkoff L, et al. Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol 2009; 83: 559-64.
22. Bresin E, Gastoldi S, Daina E, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 2009; 101: 233-8.
23. Leebeek FWG, Eikenboom JCJ. Von Willebrand's disease. N Engl J Med 2016; 375: 2067-80.
24. Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood 2017; 130: 1181-8.
25. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood 2017; 129: 2836-46